These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28284377)

  • 21. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
    Negri AL
    J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifibrotic Agents for the Management of CKD: A Review.
    Ruiz-Ortega M; Lamas S; Ortiz A
    Am J Kidney Dis; 2022 Aug; 80(2):251-263. PubMed ID: 34999158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Antoniu SA
    Expert Opin Investig Drugs; 2006 Jul; 15(7):823-8. PubMed ID: 16787145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold.
    Bülow RD; Boor P
    J Histochem Cytochem; 2019 Sep; 67(9):643-661. PubMed ID: 31116062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.
    McGowan TA; Zhu Y; Sharma K
    Curr Diab Rep; 2004 Dec; 4(6):447-54. PubMed ID: 15539010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease.
    Guan T; Gao B; Chen G; Chen X; Janssen M; Uttarwar L; Ingram AJ; Krepinsky JC
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1466-76. PubMed ID: 23946291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats.
    Wang DT; Huang RH; Cheng X; Zhang ZH; Yang YJ; Lin X
    Int Immunopharmacol; 2015 May; 26(1):4-12. PubMed ID: 25744602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.
    Takakura K; Tahara A; Sanagi M; Itoh H; Tomura Y
    Ren Fail; 2012; 34(10):1309-16. PubMed ID: 23002925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.
    Kok HM; Falke LL; Goldschmeding R; Nguyen TQ
    Nat Rev Nephrol; 2014 Dec; 10(12):700-11. PubMed ID: 25311535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney fibrosis: from mechanisms to therapeutic medicines.
    Huang R; Fu P; Ma L
    Signal Transduct Target Ther; 2023 Mar; 8(1):129. PubMed ID: 36932062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BMP1 inhibitor UK383,367 attenuates renal fibrosis and inflammation in CKD.
    Bai M; Lei J; Wang S; Ding D; Yu X; Guo Y; Chen S; Du Y; Li D; Zhang Y; Huang S; Jia Z; Zhang A
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1430-F1438. PubMed ID: 31545926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal Fibrosis: Common Enemy of Many Origins.
    Hewitt SM; Schaefer L
    J Histochem Cytochem; 2019 Sep; 67(9):621. PubMed ID: 31451045
    [No Abstract]   [Full Text] [Related]  

  • 33. Transforming growth factor β (TGFβ) and related molecules in chronic kidney disease (CKD).
    Huynh P; Chai Z
    Clin Sci (Lond); 2019 Jan; 133(2):287-313. PubMed ID: 30683713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antifibrotic and anti-inflammatory effects of icariin on the kidney in a unilateral ureteral obstruction mouse model.
    Chen HA; Chen CM; Guan SS; Chiang CK; Wu CT; Liu SH
    Phytomedicine; 2019 Jun; 59():152917. PubMed ID: 30978648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.
    Lv W; Fan F; Wang Y; Gonzalez-Fernandez E; Wang C; Yang L; Booz GW; Roman RJ
    Physiol Genomics; 2018 Jan; 50(1):20-34. PubMed ID: 29127220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural products for the prevention and treatment of kidney disease.
    Chen DQ; Hu HH; Wang YN; Feng YL; Cao G; Zhao YY
    Phytomedicine; 2018 Nov; 50():50-60. PubMed ID: 30466992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model.
    Yang M; Chen G; Zhang X; Guo Y; Yu Y; Tian L; Chang S; Chen ZK
    Pharmacol Res; 2019 Apr; 142():192-204. PubMed ID: 30807866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of renal fibrosis.
    Hysi E; Yuen DA
    Curr Opin Nephrol Hypertens; 2020 Nov; 29(6):599-607. PubMed ID: 33009130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular communication network factor 2 (CCN2) promotes the progression of acute kidney injury to chronic kidney disease.
    Inoue T; Kusano T; Amano H; Nakamoto H; Okada H
    Biochem Biophys Res Commun; 2019 Sep; 517(1):96-102. PubMed ID: 31320136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.